These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28344866)

  • 1. CD13
    Zhang J; Xu X; Shi M; Chen Y; Yu D; Zhao C; Gu Y; Yang B; Guo S; Ding G; Jin G; Wu CL; Zhu M
    Oncoimmunology; 2017; 6(2):e1258504. PubMed ID: 28344866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
    Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
    J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCL2 produced by pancreatic ductal adenocarcinoma is essential for the accumulation and activation of monocytic myeloid-derived suppressor cells.
    Gu H; Deng W; Zheng Z; Wu K; Sun F
    Immun Inflamm Dis; 2021 Dec; 9(4):1686-1695. PubMed ID: 34525267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LAL deficiency induced myeloid-derived suppressor cells as targets and biomarkers for lung cancer.
    Zhao T; Liu S; Hanna NH; Jalal S; Ding X; Wan J; Yan C; Du H
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD45
    Mao FY; Zhao YL; Lv YP; Teng YS; Kong H; Liu YG; Wu XL; Hao CJ; Chen W; Duan MB; Han B; Ma Q; Wang TT; Peng LS; Zhang JY; Cheng P; Su CY; Fu XL; Zou QM; Guo G; Guo XL; Zhuang Y
    Cell Death Dis; 2018 Jul; 9(7):763. PubMed ID: 29988030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma.
    Holokai L; Chakrabarti J; Lundy J; Croagh D; Adhikary P; Richards SS; Woodson C; Steele N; Kuester R; Scott A; Khreiss M; Frankel T; Merchant J; Jenkins BJ; Wang J; Shroff RT; Ahmad SA; Zavros Y
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33348809
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of myeloid leukocytes and soluble mediators in pancreatic cancer: importance of myeloid-derived suppressor cells.
    Karakhanova S; Link J; Heinrich M; Shevchenko I; Yang Y; Hassenpflug M; Bunge H; von Ahn K; Brecht R; Mathes A; Maier C; Umansky V; Werner J; Bazhin AV
    Oncoimmunology; 2015 Apr; 4(4):e998519. PubMed ID: 26137414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCR4
    Sharma V; Sachdeva N; Gupta V; Nada R; Jacob J; Sahni D; Aggarwal A
    Immunobiology; 2022 May; 227(3):152210. PubMed ID: 35358941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer.
    Song J; Lee J; Kim J; Jo S; Kim YJ; Baek JE; Kwon ES; Lee KP; Yang S; Kwon KS; Kim DU; Kang TH; Park YY; Chang S; Cho HJ; Kim SC; Koh SS; Kim S
    Oncotarget; 2016 Aug; 7(32):51840-51853. PubMed ID: 27322081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity.
    Okabe J; Kodama T; Sato Y; Shigeno S; Matsumae T; Daiku K; Sato K; Yoshioka T; Shigekawa M; Higashiguchi M; Kobayashi S; Hikita H; Tatsumi T; Okamoto T; Satoh T; Eguchi H; Akira S; Takehara T
    J Exp Clin Cancer Res; 2023 Oct; 42(1):262. PubMed ID: 37814340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perineural Invasion Reprograms the Immune Microenvironment through Cholinergic Signaling in Pancreatic Ductal Adenocarcinoma.
    Yang MW; Tao LY; Jiang YS; Yang JY; Huo YM; Liu DJ; Li J; Fu XL; He R; Lin C; Liu W; Zhang JF; Hua R; Li Q; Jiang SH; Hu LP; Tian GA; Zhang XX; Niu N; Lu P; Shi J; Xiao GG; Wang LW; Xue J; Zhang ZG; Sun YW
    Cancer Res; 2020 May; 80(10):1991-2003. PubMed ID: 32098780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Circulating Myeloid Suppressor Cells and Their Role in Tumour Immunology].
    Pilatova K; Budinská E; Bensciková B; Nenutil R; Šefr R; Fedorová L; Hanáková B; Brychtová V; Zdražilová Dubská L
    Klin Onkol; 2017; 30(Supplementum1):166-169. PubMed ID: 28471197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients.
    Wu L; Liu H; Guo H; Wu Q; Yu S; Qin Y; Wang G; Wu Q; Zhang R; Wang L; Zhang L; Liu C; Jiao S; Liu T
    Oncol Lett; 2018 Jun; 15(6):9507-9515. PubMed ID: 29844835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
    Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
    J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview.
    Panchal K; Sahoo RK; Gupta U; Chaurasiya A
    Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer.
    Xu XD; Hu J; Wang M; Peng F; Tian R; Guo XJ; Xie Y; Qin RY
    Hepatobiliary Pancreat Dis Int; 2016 Feb; 15(1):99-105. PubMed ID: 26818550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
    Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
    Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD33
    Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
    Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloid-Derived Suppressor Cells and Pancreatic Cancer: Implications in Novel Therapeutic Approaches.
    Thyagarajan A; Alshehri MSA; Miller KLR; Sherwin CM; Travers JB; Sahu RP
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31652904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deciphering the Crosstalk Between Myeloid-Derived Suppressor Cells and Regulatory T Cells in Pancreatic Ductal Adenocarcinoma.
    Siret C; Collignon A; Silvy F; Robert S; Cheyrol T; André P; Rigot V; Iovanna J; van de Pavert S; Lombardo D; Mas E; Martirosyan A
    Front Immunol; 2019; 10():3070. PubMed ID: 32038621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.